Abstract 29P
Background
Comprehensive genomic testing is not considered standard of care for patients with small cell lung cancer (SCLC), as no molecular targeted therapies have been approved. Currently there is limited data on the clinical impact of molecular co-alterations in SCLC.
Methods
Patients with extensive-stage SCLC undergoing panel sequencing at initial diagnosis were enrolled in the study between December 1st, 2022, and December 1st, 2024. The panel sequencing was based on the examination of 324 genes and the introns of 34 genes known to be involved in rearrangements. Clinical data, including overall survival (OS) and real-world progression-free survival (rwPFS) to different treatment lines, were retrospectively assessed. Multivariate Cox regression models included patient characteristics, specific two-way interactions, OS, TMB, PD-L1 status, and molecular co-alterations detected by next-generation sequencing.
Results
A total of 29 patients with SCLC were analyzed, 18 (62%) males with a median age of 62 years (range: 41-78). Further molecular subgroups were classified based on their genomic co-alteration profile: 5 (17%) patients with NOTCH1/RB1/TP53 co-mutations, 4 (14%) patients with CREBBP/RB1/TP53 and 4 (14%) patients with PTEN/RB1/TP53 co-mutations. Median overall survival (mOS) was shortest in patients with CREBBP/RB1/TP53 at 3 months (ms) followed by patients with PTEN/RB1/TP53 with an mOS of 9 ms. The mOS across all enrolled patients was 14ms. The rwPFS to first-line treatment (rwPFS-1) was shortest in the PTEN/RB1/TP53 subgroup at 5.5 ms followed by 6 ms in both the NOTCH1/RB1/TP53 and CREBBP/RB1/TP53 subgroups. rwPFS-2 was 4.5 ms across all three subgroups.
Conclusions
Patients with co-alterations in any of the three genes PTEN, NOTCH1, or CREBBP to RB1 or TP53 showed inferior median overall survival (mOS), underlining that these co-alterations are poor risk factors associated with a dismal prognosis. Our findings based on real-world data indicate that the use of panel sequencing in extensive-stage SCLC patients identifies co-mutated subgroups associated with therapy resistance to current standard treatments and highlights the unmet need for targeted therapeutic strategies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
142P - Lipidomic signature in response to omega-3 fatty acids and γ-linolenic acid supplementation in breast cancer patients receiving aromatase inhibitors
Presenter: Vesna Vucic
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
Presenter: Simone Rota
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Is it time to incorporate next generation sequencing of body fluids for detection of circulating tumor DNA (ctDNA) alterations?
Presenter: Aditya Shreenivas
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Unveiling the molecular landscape of head and neck cancer: Pathway dysregulations and potential therapeutic targets
Presenter: Rajeev Vijayakumar
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - ESR1 fusions as potential mechanism of resistance to endocrine therapy in metastatic breast cancer
Presenter: Sewanti Limaye
Session: Cocktail & Poster Display session
Resources:
Abstract
147P - Clinical characteristics and outcomes in non-small cell lung cancer patients harboring rare mutations: A single center real-world data
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Diversity of genomic mechanisms of resistance to endocrine therapy in ER+ breast cancer
Presenter: Prithika Sritharan
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Assessing treatment options for gynaecological cancers (GC) using next-generation sequencing (NGS): A real-world analysis
Presenter: Álvaro García
Session: Cocktail & Poster Display session
Resources:
Abstract
150P - Prevalence of DPYD variants in 1478 cancer patients receiving fluoropyrimidine chemotherapy: A real-world data analysis
Presenter: Bahaaeldin Baraka
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Unravelling the limitations of next-generation sequencing (NGS)-based liquid biopsy (LB) across solid tumors: The PREICO-LB project
Presenter: Cinta Hierro
Session: Cocktail & Poster Display session
Resources:
Abstract